DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
8	ハンチントン病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02519036 (ClinicalTrials.gov)	August 6, 2015	1/8/2015	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients With Early Manifest Huntington's Disease	Huntington's Disease	Drug: ISIS 443139 10 mg;Drug: ISIS 443139 30 mg;Drug: ISIS 443139 60 mg;Drug: ISIS 443139 90 mg;Drug: ISIS 443139 120 mg;Other: Placebo	Ionis Pharmaceuticals, Inc.	NULL	Completed	25 Years	65 Years	All	46	Phase 1;Phase 2	Canada;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02519036
(ClinicalTrials.gov)

August 6, 2015

1/8/2015

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients With Early Manifest Huntington's Disease

Huntington's Disease

Drug: ISIS 443139 10 mg;Drug: ISIS 443139 30 mg;Drug: ISIS 443139 60 mg;Drug: ISIS 443139 90 mg;Drug: ISIS 443139 120 mg;Other: Placebo

Ionis Pharmaceuticals, Inc.

NULL

Completed

25 Years

65 Years

All

Phase 1;Phase 2

Canada;Germany;United Kingdom